P1115 is a Phase I/II, multi-center, proof-of-concept study that will explore the effects of early intensive antiretroviral therapy on achieving HIV remission in neonates. The study will also assess the safety and pharmacokinetics of early intensive antiretroviral therapy in neonates.
Main Objectives:
For further information please refer to: IMPAACT Study P1115
Main Objectives:
- To assess HIV remission among HIV-infected neonates who initiate ART within 48 hours of birth. For purposes of this protocol, remission is defined as having no confirmed plasma HIV RNA ≥ LOD for 48 weeks following ART cessation.
For further information please refer to: IMPAACT Study P1115
